Richard W. Olsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard W. Olsen has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Martin Wallner
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA
9 shared publications Jing Liang
Titus Family Department of Clinical Pharmacy, School of Pharmacy, USC, Los Angeles, CA, 90089, USA
7 shared publications- Antonio V. Delgado-Escueta
University of California, Los Angeles, California, U.S.A.
5 shared publications Hongbing Wang
Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA
5 shared publicationsIgor Spigelman
5 shared publications- Werner Sieghart
Medical University of Vienna Vienna Austria
5 shared publications
Latest Publications
- 1 March 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 267, 113630
Flavonoid compounds isolated from Tibetan herbs, binding to GABAA receptor with anxiolytic property
- 1 March 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 267, 113630
Flavonoid compounds isolated from Tibetan herbs, binding to GABAA receptor with anxiolytic property
- 1 July 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (S3) , S144
Cryo-electron microscopy reveals informative details of GABAA receptor structural pharmacology: implications for drug discovery
- 1 July 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (S3) , S144
Cryo-electron microscopy reveals informative details of GABAA receptor structural pharmacology: implications for drug discovery
- 18 September 2018
- Published by Elsevier in Phytomedicine
- Vol. 50, 1-7
Flavonoids isolated from Tibetan medicines, binding to GABAA receptor and the anticonvulsant activity
- 18 September 2018
- Published by Elsevier in Phytomedicine
- Vol. 50, 1-7
Flavonoids isolated from Tibetan medicines, binding to GABAA receptor and the anticonvulsant activity
- Top Cited Papers
- 1 July 2018
- Published by Elsevier in Neuropharmacology
- Vol. 136, 10-22
GABAA receptor: Positive and negative allosteric modulators
- 1 July 2018
- Published by Elsevier in Neuropharmacology
- Vol. 136, 10-22
Top Cited PapersGABAA receptor: Positive and negative allosteric modulators
- Open Access
- 20 September 2017
- Published by Springer Nature in Molecular Brain
- Vol. 10 (1) , 1-20
Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model
GABAergic inhibitory transmission is involved in the acute and chronic effects of ethanol on the brain and behavior. One-dose ethanol exposure induces transient plastic changes in GABAA receptor subunit levels, composition, and regional and subcellular localization. Rapid down-regulation of early responder δ subunit-containing GABAA receptor subtypes mediating ethanol-sensitive tonic inhibitory currents in critical neuronal circuits corresponds to rapid tolerance to ethanol’s behavioral responses. Slightly slower, α1 subunit-containing GABAA receptor subtypes mediating ethanol-insensitive synaptic inhibition are down-regulated, corresponding to tolerance to additional ethanol behaviors plus cross-tolerance to other GABAergic drugs including benzodiazepines, anesthetics, and neurosteroids, especially sedative-hypnotic effects. Compensatory up-regulation of synaptically localized α4 and α2 subunit-containing GABAA receptor subtypes, mediating ethanol-sensitive synaptic inhibitory currents follow, but exhibit altered physio-pharmacology, seizure susceptibility, hyperexcitability, anxiety, and tolerance to GABAergic positive allosteric modulators, corresponding to heightened alcohol withdrawal syndrome. All these changes (behavioral, physiological, and biochemical) induced by ethanol administration are transient and return to normal in a few days. After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life. We conclude that the ethanol-induced changes in GABAA receptors represent aberrant plasticity contributing critically to ethanol dependence and increased voluntary consumption. We suggest that the craving, drug-seeking, and increased consumption in the rat model are tied to ethanol-induced plastic changes in GABAA receptors, importantly the development of ethanol-sensitive synaptic GABAA receptor-mediating inhibitory currents that participate in maintained positive reward actions of ethanol on critical neuronal circuits. These probably disinhibit nerve endings of inhibitory GABAergic neurons on dopamine reward circuit cells, and limbic system circuits mediating anxiolysis in hippocampus and amygdala. We further suggest that the GABAA receptors contributing to alcohol dependence in the rat and presumably in human alcohol use disorders (AUD) are the ethanol-induced up-regulated subtypes containing α4 and most importantly α2 subunits. These mediate critical aspects of the positive reinforcement of ethanol in the dependent chronic user while alleviating heightened withdrawal symptoms experienced whenever ethanol is absent. The speculative conclusions based on firm observations are readily testable.
- 20 September 2017
- Published by Springer Nature in Molecular Brain
- Vol. 10 (1) , 1-20
Open AccessRole of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model
GABAergic inhibitory transmission is involved in the acute and chronic effects of ethanol on the brain and behavior. One-dose ethanol exposure induces transient plastic changes in GABAA receptor subunit levels, composition, and regional and subcellular localization. Rapid down-regulation of early responder δ subunit-containing GABAA receptor subtypes mediating ethanol-sensitive tonic inhibitory currents in critical neuronal circuits corresponds to rapid tolerance to ethanol’s behavioral responses. Slightly slower, α1 subunit-containing GABAA receptor subtypes mediating ethanol-insensitive synaptic inhibition are down-regulated, corresponding to tolerance to additional ethanol behaviors plus cross-tolerance to other GABAergic drugs including benzodiazepines, anesthetics, and neurosteroids, especially sedative-hypnotic effects. Compensatory up-regulation of synaptically localized α4 and α2 subunit-containing GABAA receptor subtypes, mediating ethanol-sensitive synaptic inhibitory currents follow, but exhibit altered physio-pharmacology, seizure susceptibility, hyperexcitability, anxiety, and tolerance to GABAergic positive allosteric modulators, corresponding to heightened alcohol withdrawal syndrome. All these changes (behavioral, physiological, and biochemical) induced by ethanol administration are transient and return to normal in a few days. After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life. We conclude that the ethanol-induced changes in GABAA receptors represent aberrant plasticity contributing critically to ethanol dependence and increased voluntary consumption. We suggest that the craving, drug-seeking, and increased consumption in the rat model are tied to ethanol-induced plastic changes in GABAA receptors, importantly the development of ethanol-sensitive synaptic GABAA receptor-mediating inhibitory currents that participate in maintained positive reward actions of ethanol on critical neuronal circuits. These probably disinhibit nerve endings of inhibitory GABAergic neurons on dopamine reward circuit cells, and limbic system circuits mediating anxiolysis in hippocampus and amygdala. We further suggest that the GABAA receptors contributing to alcohol dependence in the rat and presumably in human alcohol use disorders (AUD) are the ethanol-induced up-regulated subtypes containing α4 and most importantly α2 subunits. These mediate critical aspects of the positive reinforcement of ethanol in the dependent chronic user while alleviating heightened withdrawal symptoms experienced whenever ethanol is absent. The speculative conclusions based on firm observations are readily testable.
- 1 January 2015
- Published by Elsevier
- Vol. 73, 167-202
Allosteric Ligands and Their Binding Sites Define γ-Aminobutyric Acid (GABA) Type A Receptor Subtypes
- 1 January 2015
- Published by Elsevier
- Vol. 73, 167-202
Allosteric Ligands and Their Binding Sites Define γ-Aminobutyric Acid (GABA) Type A Receptor Subtypes
- 12 July 2014
- Published by Springer Nature in Neurochemical Research
- Vol. 39 (10) , 1924-1941
Analysis of γ-Aminobutyric Acid (GABA) Type A Receptor Subtypes Using Isosteric and Allosteric Ligands
The GABAA receptors (GABAARs) play an important role in inhibitory transmission in the brain. The GABAARs could be identified using a medicinal chemistry approach to characterize with a series of chemical structural analogues, some identified in nature, some synthesized, to control the structural conformational rigidity/flexibility so as to define the ‘receptor-specific’ GABA agonist ligand structure. In addition to the isosteric site ligands, these ligand-gated chloride ion channel proteins exhibited modulation by several chemotypes of allosteric ligands, that help define structure and function. The channel blocker picrotoxin identified a noncompetitive channel blocker site in GABAARs. This ligand site is located in the transmembrane channel pore, whereas the GABA agonist site is in the extracellular domain at subunit interfaces, a site useful for low energy coupled conformational changes of the functional channel domain. Also in the trans-membrane domain are allosteric modulatory ligand sites, mostly positive, for diverse chemotypes with general anesthetic efficacy, namely, the volatile and intravenous agents: barbiturates, etomidate, propofol, long-chain alcohols, and neurosteroids. The last are apparent endogenous positive allosteric modulators of GABAARs. These binding sites depend on the GABAAR heteropentameric subunit composition, i.e., subtypes. Two classes of pharmacologically very important allosteric modulatory ligand binding site reside in the extracellular domain at modified agonist sites at other subunit interfaces: the benzodiazepine site, and the low-dose ethanol site. The benzodiazepine site is specific for certain subunit combination subtypes, mainly synaptically localized. In contrast, the low-dose (high affinity) ethanol site(s) is found at a modified benzodiazepine site on different, extrasynaptic, subtypes.
- 12 July 2014
- Published by Springer Nature in Neurochemical Research
- Vol. 39 (10) , 1924-1941
Analysis of γ-Aminobutyric Acid (GABA) Type A Receptor Subtypes Using Isosteric and Allosteric Ligands
The GABAA receptors (GABAARs) play an important role in inhibitory transmission in the brain. The GABAARs could be identified using a medicinal chemistry approach to characterize with a series of chemical structural analogues, some identified in nature, some synthesized, to control the structural conformational rigidity/flexibility so as to define the ‘receptor-specific’ GABA agonist ligand structure. In addition to the isosteric site ligands, these ligand-gated chloride ion channel proteins exhibited modulation by several chemotypes of allosteric ligands, that help define structure and function. The channel blocker picrotoxin identified a noncompetitive channel blocker site in GABAARs. This ligand site is located in the transmembrane channel pore, whereas the GABA agonist site is in the extracellular domain at subunit interfaces, a site useful for low energy coupled conformational changes of the functional channel domain. Also in the trans-membrane domain are allosteric modulatory ligand sites, mostly positive, for diverse chemotypes with general anesthetic efficacy, namely, the volatile and intravenous agents: barbiturates, etomidate, propofol, long-chain alcohols, and neurosteroids. The last are apparent endogenous positive allosteric modulators of GABAARs. These binding sites depend on the GABAAR heteropentameric subunit composition, i.e., subtypes. Two classes of pharmacologically very important allosteric modulatory ligand binding site reside in the extracellular domain at modified agonist sites at other subunit interfaces: the benzodiazepine site, and the low-dose ethanol site. The benzodiazepine site is specific for certain subunit combination subtypes, mainly synaptically localized. In contrast, the low-dose (high affinity) ethanol site(s) is found at a modified benzodiazepine site on different, extrasynaptic, subtypes.
- 24 October 2013
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 38 (3) , 595-603
Structural Models of Ligand‐Gated Ion Channels: Sites of Action for Anesthetics and Ethanol
The molecular mechanism(s) of action of anesthetic, and especially, intoxicating doses of alcohol (ethanol [EtOH]) have been of interest even before the advent of theResearchSociety onAlcoholism. Recent physiological, genetic, and biochemical studies have pin‐pointed molecular targets for anesthetics andEtOHin the brain as ligand‐gated ion channel (LGIC) membrane proteins, especially the pentameric (5 subunit)Cys‐loop superfamily of neurotransmitter receptors including nicotinic acetylcholine (nAChRs),GABAA(GABAARs), and glycine receptors (GlyRs). The ability to demonstrate molecular and structural elements of these proteins critical for the behavioral effects of these drugs on animals and humans provides convincing evidence for their role in the drugs' actions. Amino acid residues necessary for pharmacologically relevant allosteric modulation ofLGICfunction by anesthetics andEtOHhave been identified in these channel proteins. Site‐directed mutagenesis revealed potential allosteric modulatory sites in both the trans‐membrane domain (TMD) and extracellular domain (ECD). Potential sites of action and binding have been deduced from homology modeling of otherLGICs with structures known from crystallography and cryo‐electron microscopy studies. Direct information about ligand binding in theTMDhas been obtained by photoaffinity labeling, especially inGABAARs. Recent structural information from crystallized procaryotic (ELICandGLIC) and eukaryotic (GluCl)LGICs allows refinement of the structural models including evaluation of possible sites ofEtOHaction.
- 24 October 2013
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 38 (3) , 595-603
Structural Models of Ligand‐Gated Ion Channels: Sites of Action for Anesthetics and Ethanol
The molecular mechanism(s) of action of anesthetic, and especially, intoxicating doses of alcohol (ethanol [EtOH]) have been of interest even before the advent of theResearchSociety onAlcoholism. Recent physiological, genetic, and biochemical studies have pin‐pointed molecular targets for anesthetics andEtOHin the brain as ligand‐gated ion channel (LGIC) membrane proteins, especially the pentameric (5 subunit)Cys‐loop superfamily of neurotransmitter receptors including nicotinic acetylcholine (nAChRs),GABAA(GABAARs), and glycine receptors (GlyRs). The ability to demonstrate molecular and structural elements of these proteins critical for the behavioral effects of these drugs on animals and humans provides convincing evidence for their role in the drugs' actions. Amino acid residues necessary for pharmacologically relevant allosteric modulation ofLGICfunction by anesthetics andEtOHhave been identified in these channel proteins. Site‐directed mutagenesis revealed potential allosteric modulatory sites in both the trans‐membrane domain (TMD) and extracellular domain (ECD). Potential sites of action and binding have been deduced from homology modeling of otherLGICs with structures known from crystallography and cryo‐electron microscopy studies. Direct information about ligand binding in theTMDhas been obtained by photoaffinity labeling, especially inGABAARs. Recent structural information from crystallized procaryotic (ELICandGLIC) and eukaryotic (GluCl)LGICs allows refinement of the structural models including evaluation of possible sites ofEtOHaction.
- Open Access
- 5 December 2012
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 32 (49) , 17874-17881
Ethanol Promotes Clathrin Adaptor-Mediated Endocytosis via the Intracellular Domain of δ-Containing GABAAReceptors
Pharmacological and genetic evidence reveals that GABAAreceptor (GABAA-R) expression and localization are modulated in response to acute and chronic ethanol (EtOH) exposure. To determine molecular mechanisms of GABAA-R plasticity in response toin vivoacute EtOH, we measured early time changes in GABAA-R subunit localization. Single doses of EtOH (3 g/kg via i.p. injection in rats) produced decreases in surface levels of GABAA-R α4 and δ subunits at 5–15 min post-EtOH in hippocampus CA1 and dentate gyrus, verifying our earlier report (Liang et al., 2007). Here we also examined the β3 subunit and its phosphorylation state during internalization. β3 also was internalized during 5–15 min after EtOH exposure, while phosphorylation of β3 was increased, then decreased at later times, ruling out β3 dephosphorylation-dependent endocytosis. As early as 5 min post-EtOH, there is an initial increase in association between the δ subunits with clathrin adaptor proteins AP2-μ2 revealed by coimmunoprecipitation, followed by a decrease in association 15 min post-EtOH.In vitrostudies using glutathioneS-transferase fused to the δ subunit intracellular domain (ICD) show that two regions, one containing a classical YxxΦ motif and the other an atypical R/K-rich motif, directly and differentially bind to AP2-μ2, with the former YRSV exhibiting higher affinity. Mutating both regions in the δ-ICD abolishes μ2 binding, providing a possible mechanism that can explain the rapid downregulation of extrasynaptic α4βδ-GABAA-R followingin vivoEtOH administration, in which the δ-ICD increases in affinity for clathrin AP2-μ2 leading to endocytosis.
- 5 December 2012
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 32 (49) , 17874-17881
Open AccessEthanol Promotes Clathrin Adaptor-Mediated Endocytosis via the Intracellular Domain of δ-Containing GABAAReceptors
Pharmacological and genetic evidence reveals that GABAAreceptor (GABAA-R) expression and localization are modulated in response to acute and chronic ethanol (EtOH) exposure. To determine molecular mechanisms of GABAA-R plasticity in response toin vivoacute EtOH, we measured early time changes in GABAA-R subunit localization. Single doses of EtOH (3 g/kg via i.p. injection in rats) produced decreases in surface levels of GABAA-R α4 and δ subunits at 5–15 min post-EtOH in hippocampus CA1 and dentate gyrus, verifying our earlier report (Liang et al., 2007). Here we also examined the β3 subunit and its phosphorylation state during internalization. β3 also was internalized during 5–15 min after EtOH exposure, while phosphorylation of β3 was increased, then decreased at later times, ruling out β3 dephosphorylation-dependent endocytosis. As early as 5 min post-EtOH, there is an initial increase in association between the δ subunits with clathrin adaptor proteins AP2-μ2 revealed by coimmunoprecipitation, followed by a decrease in association 15 min post-EtOH.In vitrostudies using glutathioneS-transferase fused to the δ subunit intracellular domain (ICD) show that two regions, one containing a classical YxxΦ motif and the other an atypical R/K-rich motif, directly and differentially bind to AP2-μ2, with the former YRSV exhibiting higher affinity. Mutating both regions in the δ-ICD abolishes μ2 binding, providing a possible mechanism that can explain the rapid downregulation of extrasynaptic α4βδ-GABAA-R followingin vivoEtOH administration, in which the δ-ICD increases in affinity for clathrin AP2-μ2 leading to endocytosis.
- Open Access
Effects on promoter activity of common SNPs in 5′ region of GABRB3 exon 1A
Summary: Purpose: The β3 subunit of the γ‐aminobutyric acid type A receptors (GABAA–Rs) is an essential component of GABAA–Rs in fetal, perinatal, and adult mammalian brain. Various transcripts of the β3 subunit gene (GABRB3) produce various proteins with different N‐termini. Rare variants in this N‐terminus (exon 1A and exon 2) of GABRB3 protein segregate in affected family members of two multigeneration‐multiplex families with remitting childhood absence epilepsy (rCAE), suggesting GABRB3 is a major Mendelian epilepsy gene for rare families with CAE. Therefore, the N‐terminus of GABRB3 could be important for GABRB3 regulation in development, and its alteration could produce rCAE. Herein we determine if single nucleotide polymorphisms (SNPs) within the 1,148‐bp region upstream from exon 1A influence the expression of GABRB3.Methods: We studied luciferase reporter expression for promoter activity, 1,148‐bp upstream from exon 1A, using human embryonic kidney 293 cells. We generated constructs of the promoter region and compared different SNP haplotypes in 48 patients with rCAE. Next, we compared frequencies of rs20317, located in the core promoter region, and rs4906902, located in the enhancer region between 48 patients with rCAE and >500 healthy controls matched for ethnicity and ancestral origin.Key Findings: Highest luciferase expression occurred 230‐bp upstream of exon 1A. The construct that excluded this region lost luciferase activity. Therefore, this region contains the core promoter of exon 1A. Allele C but not allele G (rs20317) significantly increased luciferase expression activity. Allele C creates binding motifs for cMYB and EGR‐3. Longer constructs overlapping this region have a binding motif for REST (RE1‐silencing transcription factor), a critical epigenetic modulator for neuronal genes. REST represses expression of neuronal genes in nonneuronal tissues, resulting in reduced luciferase expression activity. Even in the suppressed condition, the longer construct enhanced luciferase expression activity of the shorter construct, which excluded the distal end containing rs4906902. However, allele frequencies of rs20317 and rs4906902 were not significantly associated with 48 rCAE patients in comparison to >500 controls matched for ethnicity and ancestral origin.Significance: Common SNPs in the promoter region increase luciferase expression activity. An epigenetic modulator, REST, specifically alters expression of GABRB3 exon 1A transcripts, suggesting epigenetic regulation by REST dominantly controls the expression of GABRB3 variant 2 transcript in early life GABAA signaling. Abnormal epigenetic regulation could be involved in absence seizures.
Open AccessEffects on promoter activity of common SNPs in 5′ region of GABRB3 exon 1A
Summary: Purpose: The β3 subunit of the γ‐aminobutyric acid type A receptors (GABAA–Rs) is an essential component of GABAA–Rs in fetal, perinatal, and adult mammalian brain. Various transcripts of the β3 subunit gene (GABRB3) produce various proteins with different N‐termini. Rare variants in this N‐terminus (exon 1A and exon 2) of GABRB3 protein segregate in affected family members of two multigeneration‐multiplex families with remitting childhood absence epilepsy (rCAE), suggesting GABRB3 is a major Mendelian epilepsy gene for rare families with CAE. Therefore, the N‐terminus of GABRB3 could be important for GABRB3 regulation in development, and its alteration could produce rCAE. Herein we determine if single nucleotide polymorphisms (SNPs) within the 1,148‐bp region upstream from exon 1A influence the expression of GABRB3.Methods: We studied luciferase reporter expression for promoter activity, 1,148‐bp upstream from exon 1A, using human embryonic kidney 293 cells. We generated constructs of the promoter region and compared different SNP haplotypes in 48 patients with rCAE. Next, we compared frequencies of rs20317, located in the core promoter region, and rs4906902, located in the enhancer region between 48 patients with rCAE and >500 healthy controls matched for ethnicity and ancestral origin.Key Findings: Highest luciferase expression occurred 230‐bp upstream of exon 1A. The construct that excluded this region lost luciferase activity. Therefore, this region contains the core promoter of exon 1A. Allele C but not allele G (rs20317) significantly increased luciferase expression activity. Allele C creates binding motifs for cMYB and EGR‐3. Longer constructs overlapping this region have a binding motif for REST (RE1‐silencing transcription factor), a critical epigenetic modulator for neuronal genes. REST represses expression of neuronal genes in nonneuronal tissues, resulting in reduced luciferase expression activity. Even in the suppressed condition, the longer construct enhanced luciferase expression activity of the shorter construct, which excluded the distal end containing rs4906902. However, allele frequencies of rs20317 and rs4906902 were not significantly associated with 48 rCAE patients in comparison to >500 controls matched for ethnicity and ancestral origin.Significance: Common SNPs in the promoter region increase luciferase expression activity. An epigenetic modulator, REST, specifically alters expression of GABRB3 exon 1A transcripts, suggesting epigenetic regulation by REST dominantly controls the expression of GABRB3 variant 2 transcript in early life GABAA signaling. Abnormal epigenetic regulation could be involved in absence seizures.